Publication | Open Access

Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors

Cancer ImmunosurveillancePd-l1 ExpressionMedicineImmunologyTumor ImmunityImmune SurveillanceMulticenter ComparisonImmune Checkpoint InhibitorCancer TreatmentNsclc PatientsImmunotherapyOncologyRadiation Oncology